Tag Archives: Novo Nordisk

Novo Rebranding; Corbus Topline Ph1b CB1 Data; New Foundayo DTC TV Ads; New Alveus Ph2 Obesity Study; Beta Bionics Patch Pump FDA Clearance; Senseonics Integrates with Beta Bionics’s iLet AID; September CHMP Agenda

A series of cardiometabolic-related news items has been observed from Novo Nordisk, Corbus Pharmaceuticals, Lilly, Alveus Therapeutics, Beta Bionics, Senseonics, and EMA. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Novo to Announce Org Changes; Novartis/Ionis Pelacarsen Updates

Two cardiometabolic-related news items have been observed: Novo Nordisk announced a Global Town Hall meeting for its employees ahead of its upcoming CMD (view X post), and Ionis provided additional updates on pelacarsen during the Wells Fargo Healthcare Conference 2026 (view webcast). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Innovent Initiates Ph1 INHBE China-based Study in Obesity; BioLife Receives Patent for Dissolvable Obesity Medicine; Novo’s Semaglutide Approved for MASH in China

Three cardiometabolic-related news items have been observed: Innovent Biologics initiated a Ph1 FIH study of its Q3M/Q6M SC INHBE (view CT.gov record); BioLife received a US patent for its effervescent oral peptide delivery technology (view press release); and Novo Nordisk’s injectable semaglutide received approval from NMPA for the treatment of F2-F3 MASH (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Novartis’s Pelacarsen Misses Primary Endpoint; Wegovy Peds Data, Structure FIH Amylin Data; Novo Stops More CV Trials; Sernova and Seraxis to Merge

A series of cardiometabolic-related news items has been observed from Novartis, Novo Nordisk, Structure Therapeutics, and Sernova/Seraxis. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Vertex New Trial for T1DM Cell Therapy; Novo New Oral Anti-Inflammatory Study; Novo Leadership Transition; Pfizer Amylin Market-Shaping Campaign

A series of cardiometabolic-related news items has been observed from Vertex, Novo Nordisk, and Pfizer. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Lilly Orfor Obesity/ORC Prevention Study; NewAmsterdam Alzheimer’s Study; Novartis to Advance IL-6 Inhibitor to Ph3; Wegovy Pill Germany Launch; Pfizer Berobenatide Japan Studies; MiniMed CY Q2 ’26 Earnings; Novo Initiates AMBITION 7

A series of cardiometabolic-related news items has been observed from Lilly, NewAmsterdam Pharma, Novartis, Novo Nordisk, Pfizer, MiniMed, and CSPC Pharmaceutical. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Novo Discontinues Saxenda; Oral Wegovy Accepted for Review in China; Lilly Posts New China-Based Orfor Study; GSK Initiates New ALD Study

A series of cardiometabolic-related news items has been observed from Novo Nordisk, Lilly, and GSK. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Roche Licenses Muscle-Preservation AOM from Hanmi; Foundayo UK Launch; Lilly Initiates Second Ph3 Brenipatide MDD Study; Lexicon Receives Third LX9851 Milestone Payment; Biomea Completes COVALENT-211 Enrollment

A series of cardiometabolic-related news items has been observed from Roche/Hanmi, Lilly, Lexicon, and Biomea Fusion. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Novo Initiates Ph3 OASIS 5 Study; AZ Initiates Ph3 Amylin Program; Roche Makes Another Manufacturing Investment; NICE Endorses Lilly’s QW Insulin; Hansoh Discovers New Obesity Assets

A series of cardiometabolic-related news items has been observed from Novo Nordisk, AstraZeneca, Roche/Genentech, Lilly, and Hansoh Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Novo New Ph1 AOM; MiniMed Flex with Instinct CGM Now Available in US; Arrowhead Launches Redemplo in Germany; Sandoz Partners for Biosimilars; Baxfendy Misses ICER Mark

A series of cardiometabolic-related news items has been observed from Novo Nordisk, MiniMed, Arrowhead Pharmaceuticals, Sandoz/Henlius, and AstraZeneca. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here